Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Glasgow Professor discusses about new approach for CML treatment at UK conference

Speaking at the UK National Stem Cell Network conference in York later today, Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia in which a small number of cancer cells persist despite effective therapy thus preventing cure.

31 Mar 2011

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

CEL-SCI Corporation announced today that the State of Israel's Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine in Israel.

31 Mar 2011

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).

31 Mar 2011

ACR releases new guidelines for JA treatment

Several Canadian pediatric rheumatologists and health professionals played a prominent role in developing new guidelines for treating juvenile arthritis.

31 Mar 2011

Essential protein linked to TNF induced inflammation

SCIENTISTS have discovered an essential protein that controls inflammation induced by 'tumour necrosis factor' (TNF) - an important part of the body's defences against infection and a driver of cancer-associated inflammation, according to research published in Nature today (Wednesday).

31 Mar 2011

New clinical practice guidelines developed for juvenile idiopathic arthritis

The American College of Rheumatology has developed new guidelines for starting and monitoring treatments for children with juvenile idiopathic arthritis. These are the first JIA guidelines endorsed by the ACR, with the goal of broad acceptance within the rheumatology community.

30 Mar 2011

Singing reduces blood pressure prior to total knee replacement surgery

Doctors report that singing reduced the blood pressure of a 76-year-old woman who had experienced severe preoperative hypertension prior to total knee replacement surgery for osteoarthritis (OA). While the patient was unresponsive to aggressive pharmacologic interventions, the woman's blood pressure dropped dramatically when she sang several religious songs.

30 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

USPTO grants composition-of-matter patent to Zalicus 'Synavive' product

Zalicus Inc. announced today that it has been granted a composition-of-matter patent by the U.S. Patent and Trademark office covering its product candidate Synavive.

30 Mar 2011

People with arthritis can benefit from exercise

An estimated 50 million adults in the United States suffer from arthritis. According to the Centers for Disease Control, one of the best ways to combat the onset of arthritis as well as to control pain and improve function is through exercise.

29 Mar 2011

Cancer drug Gleevec may hold promise against scleroderma: Study

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.

28 Mar 2011

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.

28 Mar 2011

Lupus nephritis ESRD study finds increase in incidence rates among children, African Americans

New research documenting changes in the incidence and outcomes of end-stage renal disease in the U.S. between 1995 and 2006, found a significant increase in incidence rates among patients 5 to 39 years of age and in African Americans.

28 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

Study develops new approaches for sorting out complexities of cancer cells

New drugs that specifically target the mutated genes responsible for cancer growth have shown great success in extending the lives of patients, with far fewer side effects than conventional anti-cancer therapies. Unfortunately, many patients become resistant to these drugs due to secondary mutations.

25 Mar 2011

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Protelos has significantly greater bone-forming activity than the commonly prescribed bisphosphonate, alendronate, according to results of the largest-ever biopsy study in post-menopausal women presented today at the European Congress on Osteoporosis and Osteoarthritis in Valencia.

25 Mar 2011

$Falls history improves accuracy of fracture prediction models$

Falls history improves accuracy of fracture prediction models

Researchers from the MRC Lifecourse Epidemiology Unit in Southampton, UK, have presented a new study that shows how the inclusion of falls history, in addition to clinical risk factors (CRFs) and bone mineral density (BMD) values, would greatly improve the accuracy of fracture prediction models. The research findings were presented today at the European Congress on Osteoporosis & Osteoarthritis in Valencia, Spain.

25 Mar 2011

HCG hormone therapy may benefit patients with intractable pain

Results from a small study of intractable pain patients being treated with the human chorionic gonadotropin (HCG) hormone reported that they had experienced pain free hours in the past month. These results were presented at a poster session at the American Academy of Pain Medicine's 27th Annual Meeting.

25 Mar 2011